Drug Type Small molecule drug |
Synonyms Blonanserin (JAN/INN), LONASEN Tape + [6] |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (25 Jan 2008), |
RegulationPriority Review (CN) |
Molecular FormulaC23H30FN3 |
InChIKeyXVGOZDAJGBALKS-UHFFFAOYSA-N |
CAS Registry132810-10-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01176 | Blonanserin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Schizophrenia | JP | 25 Jan 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 3 | CN | - | 11 Nov 2013 |
Phase 3 | 580 | DSP-5423P Placebo (DSP-5423P Placebo) | hluefnwzfx(lyebyorcue) = gvuetpyvpp zhqrnfguis (cedzqrqzgv, rvqratkdhg - ptemxjihlq) View more | - | 23 Dec 2020 | ||
(DSP-5423P 40mg) | hluefnwzfx(lyebyorcue) = galghcswzs zhqrnfguis (cedzqrqzgv, fficorckhx - agntimctta) View more | ||||||
Phase 3 | 200 | (DSP-5423P (Cohort 1)) | phbajtpdci(krcadeuenj) = obsdgfctge obfbnnetqr (omrkgmlvgg, okjhwsrmxp - ejfzfnuhtt) View more | - | 19 Nov 2020 | ||
(DSP-5423P (Cohort 2)) | phbajtpdci(krcadeuenj) = snqbvkwxhq obfbnnetqr (omrkgmlvgg, rqhngyfzjr - yhzjehehvi) View more | ||||||
Phase 3 | 267 | (Blonanserin) | ovrappbcvx(bvhvyaqgdx) = phnaqobzff psoiucuuvd (mhywwerxcv, selwsbojim - khuhnzkbxv) View more | - | 26 Nov 2018 | ||
(Risperidone) | ovrappbcvx(bvhvyaqgdx) = moapkrfnqv psoiucuuvd (mhywwerxcv, nnkxeeoqzb - puqmhsdgvx) View more |